Publications & Posters - Infectious Disease
HIV p24 antigen is quantifiable at low concentrations in human cerebrospinal fluid with digital ELISA and is associated with decreased neuropsychological performance
Clinical Infectious Diseases | January 29, 2018
In this brief report, we tested cerebrospinal fluid (CSF) samples from 15 study participants for p24 antigen using a high sensitivity assay.
Retroviology | January 17, 2018
With the increasing number of therapeutic strategies tested in humans to reduce the size of the latent reservoir, the development of a robust, precise and clinical trial scalable assay that measures the frequency of infected cells carrying inducible replication-competent HIV is urgently needed. The…
High-Throughput | November 16, 2017
Procalcitonin (PCT) is well established as a highly specific biomarker for the detection of bacterial infections and sepsis. However, the currently available diagnostic tests are not able to detect very low or very early increases of PCT or even baseline levels in healthy individuals or patients…
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor
PLOS Pathogens | October 12, 2017
HIV is adept at avoiding naturally generated T cell responses; therefore, there is a need to develop HIV-specific T cells with greater potency for use in HIV cure strategies. Starting with a CD4-based chimeric antigen receptor (CAR) that was previously used without toxicity in clinical trials, we…
JCI Insight |August 17, 2017
Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus from latently infected cells using latency-reversing agents (LRAs) and immune-mediated clearance to purge reservoirs. Accurate detection of cells capable of producing viral antigens and virions, and…
American Journal of Respiratory and Critical Care Medicine | May 2017
Poster Presentation, American Thoracic Society Conference 2017 A.26 Diagnosis and Treatment of Tuberculosis, Poster Session: May 21, 2017
Current AIDS/HIV Report | April 11, 2017
The development and evaluation of strategies for HIV remission rely upon our ability to accurately and precisely quantify the size of the remaining viral reservoir.
Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab
AIDS | April 24, 2017
So far, two case reports involving HIV-infected patients with melanoma treated with ICIs have shown encouraging safety results but distinct viral effects.
Nature | March 15, 2017
Using an in vitro model of HIV-infected quiescent CD4 T cells, we reveal a gene expression signature of 103 upregulated genes that are specific for latently infected cells
Cell Reports | January 31, 2017
The presence of latent HIV-1 in infected individuals represents a major barrier preventing viral eradication. For that reason, reactivation of latent viruses in the presence of antiretroviral regimens has been proposed as a therapeutic strategy to achieve remission.